Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as in comparison with imatinib, for the primary-line treatment of CML-CP. Five hundred and nineteen sufferers with freshly diagnosed CML-CP were being randomly assigned to obtain dasatinib at a dose of one hundred mg at the time day-to-day (259 https://jonahg196wae9.plpwiki.com/user